Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 23, 2020 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300

U.S. Phase 1 trial patient enrollment to begin in the first half of 2021China Phase 1 trial enrollment ongoingKey regulatory milestone achieved to enable further study of product candidate for...
November 12, 2020 16:05 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

ON 123300, our proprietary multi-kinase inhibitor, enters into the clinic for advanced solid tumorsInvestigator-initiated study advances with combination of oral rigosertib and nivolumab in K-RAS...
November 05, 2020 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics to Provide Corporate Update and Third Quarter 2020 Financial Results on November 12, 2020

NEWTOWN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today...
October 13, 2020 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics to Present Update During the 2020 BIO Investor Forum Digital Event

NEWTOWN, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today...
September 21, 2020 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals

Company remains on track to file a US IND in Q4 2020, with commencement of a US Phase 1 study targeted for Q1 2021 NEWTOWN, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc....
September 09, 2020 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Participation at Upcoming Virtual Events

NEWTOWN, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today...
August 31, 2020 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Election of James J. Marino, JD, MBA as Chairman of the Board of Directors

NEWTOWN, Pa., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today...
August 24, 2020 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial

IV rigosertib did not meet primary endpoint of significantly improved survival versus best supportive care in higher-risk myelodysplastic syndromes (HR-MDS) Onconova will focus on promising...
August 12, 2020 16:05 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results

INSPIRE Phase 3 trial survival events reachedTopline data anticipated Q3-2020 Conference call and webcast scheduled today, August 12, at 4:30 p.m. ET NEWTOWN, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE)...
August 07, 2020 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020

NEWTOWN, Pa., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...